TGF-β1 serum concentration as a complementary diagnostic biomarker of lung cancer: Establishment of a cut-point value

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 4, 2011, Pages 238-243

  González Santiago, Ana E ^a   Mendoza Topete, Luz A ^b   Sánchez Llamas, Francisco ^b   Troyo Sanromán, Rogelio ^a   Gurrola Díaz, Carmen M ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Biomarker; Diagnosis; Lung cancer; TGF 1 serum concentration

Indexed keywords

BIOLOGICAL MARKER; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; LUNG CANCER; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LINEAR MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; ROC CURVE; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 79960682037     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20465     Document Type: Article

References (35)

1. Travis WD, Brambilla E, Mueller-Hermelink HK, Harris CC. World Health Organization Classification Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press; 2004. p 10-20.
2. Wakai K, Inoue M, Mizoue T, et al. Tobacco smoking and lung cancer risk: An evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol 2006;36:309-324.
3. Tang JH, Zhao JH, Lu JW, et al. Circulating levels of angiogenic cytokines in advanced breast cancer patients with system chemotherapy and their potential value in monitoring disease course. J Cancer Res Clin Oncol 2011;137:55-63.
4. Lawrence DA. Transforming growth factor-beta: A general review. Eur Cytokine Netw 1996;7:363-374.
5. Derinck R, Akhurst RS, Balmain A. TGF beta signaling in tumor suppression and cancer progression. Nat genet 2001;29:117-128.
6. Shim KS, Kim KH, Han WS, Park EB. Elevated serum levels of transforming growth factor beta 1 in patients with colorectal carcinoma. Its association with tumor progression and its significant decrease after radiotherapy. Cancer 1999;85:544-561.
7. Su-Ping S, Ye-Ning J, Hong-Peng Y, Yi W, Zhao D. Serum transforming growth factor beta 1 levels reflects disease status in patients with esophageal carcinoma after radiotherapy. Word J Gastroenterol 2007;13:5267-5272.
8. Li X, Yue Z, Zhang YY, et al. Elevated serum level and gene polymorphisms of TGF-beta 1 in gastric cancer. J Clin Lab Anal 2008;22:164-171.
9. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor beta1 and beta 2 in the plasma of patients with glioblastoma. J Neurooncol 2006;79:61-65.
10. Kong FM, Washington MK, Jirtle RL, Anscher MS. Plasma transforming growth factor-beta 1 reflects disease status in patients with lung cancer after radiotherapy: A possible tumor marker. Lung cancer 1996;16:47-59.
11. Kong FM, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-b1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-1719.
12. Sepúlveda-Flores RN, Vera-Cabrera L, Flores-Gutiérrez JP, et al. Obesity-related non-alcoholic steatohepatitis and TGF-beta1 serum levels in relation to morbid obesity. Ann Hepatol 2002;1:36-39.
13. Yuang Z, Wi L, Yuliang Z, et al. Analysis of serum cytoquines in patients with severe acute respiratory syndrome. Infect Immun 2004;72:4410-4415.
14. Kim YK, Lee BC, Ham BJ, et al. Increased transforming growth factor-beta1 in alcohol dependence. J Korean Med Sci 2009;24:941-944.
15. Churg A, Wang RD, Wright JL. Cigarette smoke causes small airway remodeling by direct growth factor induction and release. Proc Am Thorac Soc 2006;3:493.
16. Guo JC, Bao JF, et al. Level of serum and liver tissue TGF-beta1 in patients with liver fibrosis due to chronic hepatitis. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2008;22:354-357.
17. Suthanthiran M, Gerber LM, Schwartz JE, et al. Circulating transforming growth factor-beta1 levels and the risk for kidney disease in African Americans. Kidney Int 2009;76:72-80.
18. Yener S, Comlekci A, Akinci B, et al. Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. Hormones 2008;7:70-76.
19. Mak JC, Chan-Yeung MM, Ho SP, et al. Elevated plasma TGF-beta1 levels in patients with chronic obstructive pulmonary disease. Respir Med 2009;103:1083-1089.
20. Zhu S, Liu Y, Wang L, Meng QH. Transforming growth factorbeta1 is associated with kidney damage in patients with essential hypertension: Renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant 2008;23:2841-2846.
21. Goulet S, Bihl MP, Gambazzi F, Tamm M, Roth M. Opposite effect of corticosteroids and long-acting beta(2)-agonists on serum- and TGF-beta(1)-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 2007;210:167-176.
22. Johnson MD, Kim P, Tourtellotte W, Federspiel CF. Transforming growth factor beta and monocyte chemotactic protein-1 are elevated in cerebrospinal fluid of immunocompromised patients with HIV-1 infection. J NeuroAIDS 2004;2:33-43.
23. Dennler S, Goumans MJ, ten Dijke P. Transforming growth factor β transduction. J Leukoc Biol 2002;71:731-740.
24. Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proc Natl Acad Sci USA 2003;100:8621-8623.
25. Welch DR, Fabra A, Nakajima M. Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 1990;87:7678-7682.
26. Domagala-Kulawik J, Hoser G, Safianowska A, Grubek-Jaworska H, Chazan R. Elevated TGF-beta1 concentration in bronchoalveolar lavage fluid from patients with primary lung cancer. Arch Immunol Ther Exp 2006;54:143-147.
27. Fukuyama T, Ichiki Y, Yamada S, et al. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo/in vitro. Cancer Sci 2007;98:1048-1054.
28. Feinstein AR, Wells CK. A clinical-severity staging system for patients with lung cancer. Medicine 1990;69:1-33.
29. U.S. Preventive Services Task Force. Lung cancer screening: Recommendation statement. Ann Intern Med 2004;140:738-739.
30. Rivera MP, Detterbeck F, Mehta AC, for the American College of Chest Physicians. Diagnosis of lung cancer: The guidelines. Chest 2003;123:129S-136S.
31. Collins LG, Haines C, Perkel R, Enck RE. Lung Cancer: Diagnosis and Management. Am Fam Physician 2007;75:56-63.
32. Gavelli G, Giampalma E. Sensitivity and specificity of chest x-ray screening for lung cancer. Cancer 2000;89:2453-2456.
33. Joshi SC, Pant I, Hamzah F, Kumar G, Shukla AN. Integrated positron emission tomography/ computed tomography fusion imaging: An emerging gold standard in lung cancer. Indian J Cancer 2008;45:137-141.
34. Fujimoto K. Usefulness of contrast-enhanced magnetic resonance imaging for evaluating solitary pulmonary nodules. Cancer Imaging 2008;8:36-44.
35. Black C, de Verteuil R, Walker S, et al. Population screening for lung cancer using computed tomography, is there evidence of clinical effectiveness? A systematic review of the literature. Thorax 2007;62:131-138.